After axing its lead obesity asset last year, BioAge Labs has turned its attention to attacking inflammation in its pursuit ...

Funding to advance Phase 2 clinical trials of azelaprag, an apelin receptor (APJ) agonist, in combination with Lilly’s Zepbound (tirzepatide) and therapeutic pipeline Azelaprag improves metabolic and ...

RICHMOND, Calif.--(BUSINESS WIRE)--BioAge Labs, Inc. ("BioAge"), a clinical-stage biotechnology company developing therapeutic candidates for metabolic diseases, such as obesity, by targeting the ...

Interest in metabolic medicines is riding high, led by the popular class of weight management drugs known as GLP-1 agonists. BioAge Labs aims to help those medications work better with a lead drug ...

The combination of an experimental BioAge Labs drug with the approved Eli Lilly obesity medication Zepbound has hit a major setback: a safety signal observed in some clinical trial participants that ...

BioAge Labs (NASDAQ:BIOA) used its R&D Day event to provide an update on its lead program, BGE-102, an oral, brain-penetrant ...

Sept 26 (Reuters) - Shares of BioAge Labs (BIOA.O), opens new tab opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the ...

BioAge Labs, Inc. (NASDAQ:BIOA) is one of the 11 Best New Penny Stocks to Buy Right Now. On June 17, BioAge Labs, Inc. (NASDAQ:BIOA) announced a new initiative to profile and analyze samples from the ...

Shares of BioAge Labs (BIOA) continued to spike for the second consecutive session on Tuesday in reaction to updated results from an early-stage trial for the company’s lead asset, BGE-102, targeted ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

(Reuters) -Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...